newsfilter
← Latest News
Business Wire·

Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022

Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that